medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2022, Number 2

<< Back Next >>

An Med Asoc Med Hosp ABC 2022; 67 (2)

Stevens Johnson Syndrome-toxic epidermal necrolysis

Chávez LDD, Maya BDK, Gálvez MRE, González MA

Language: Spanish
References: 17
Page: 137-141
PDF size: 279.12 Kb.


ABSTRACT

Stevens Johnson Syndrome and toxic epidermal necrolysis are characterized by extensive epidermis necrosis, with mucosal involvement, both result due to a type IV hypersensitivity reaction. The aim is review of both diseases by presenting a clinical case of an infant with toxic epidermal necrolysis, highlighting the importance of making a timely diagnosis and treatment in a previously healthy individual, preventing complications and long-term sequels. An 8-year-old male, presents with disseminated dermatosis characterized by erythematous macules, papules, and target lesions with necrotic center which evolved to blisters and areas of epidermal detachment and positive Nikolsky sign, involving 70% of body surface area. There was history of previous treatment with ibuprofen, metamizole, trimethoprim-sulfamethoxazole and penicillin. Stevens Johnson syndrome was diagnosed, treatment with intravenous immunoglobulin therapy (2 mg/kg/día) and petrolatum gauze dressings was initiated, with good response. Conclusions: These dermatological pathologies are rare cutaneous, potentially fatal diseases. They are usually related to previous pharmacologic treatment and use of trimethoprim-sulfamethoxazole is commonly found, like in this patient.


REFERENCES

  1. Liotti L, Caimmi S, Bottau P, Bernardini R, Cardinale F, Saretta F et al. Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Acta Biomed. 2020; 90 (3-S): 52-60. Available in: https://doi.org/10.23750/abm.v90i3-S.8165

  2. Hsu DY, Brieva J, Silverberg NB, Paller AS, Silverberg JI. Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad of Dermatol. 2017; 76 (5): 811-817. Available in: https://doi.org/10.1016/j.jaad.2016.12.024

  3. Del Pozzo-Magańa BR, Lazo-Langner A. Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a literature review of current treatments. EMJ Dermatol. 2016; 4 (1): 83-89.

  4. Das S, Ramkumar R. Stevens-Johnson syndrome and toxic epidermal necrolysis in children. IPJD. 2018; 19 (1): 9-14. Available in: https://doi.org/10.4103/ijpd.IJPD_120_17

  5. Alerhand S, Casella C, Koyfman A. Stevens-Johnson syndrome and toxic epidermal necrolysis in the pediatric population. Pediatr Emerg Care. 2016; 32 (7): 472-476. Available in: https://doi: 10.1097/PEC.0000000000000840

  6. Miliszewski MA, Kirchhof MG, Sikora S, Papp A, Dutz JP. Stevens-Johnson syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention. Am J Med. 2016; 129 (11): 1221-1225. Available in: https://doi.org/10.1016/j.amjmed.2016.03.022

  7. Sibbald C, Putterman E, Micheletti R, Treat J, Castelo-Soccio L. Retrospective review of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis cases at a pediatric tertiary care institution. Pediatr Dermatol. 2020; 37 (3): 461-466. Available in: https://doi.org/10.1111/pde.14118

  8. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010; 39 (5): 1-11. Available in: 10.1186/1750-1172-5-39

  9. Carrasquillo OY, Santiago-Vazquez M, Cardona R, Cruz-Manzano M, Figueroa LD. Stevens-Johnsos syndrome and toxic epidermal necrolysis: a retrospective descriptive study. Int J Dermatol. 2019; 58 (11): 1293. Available in: 10.1111/ijd.14493

  10. Chu-Chi L, Chun-Bing C, Chuang-Wei W, Shuen-Iu H, Wen-Hung C. Stevens-Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategies. Expert Rev Clin Immunol. 2020; 16 (4): 373-387. Available in: https://doi.org/10.1080/1744666X.2020.1740591

  11. Zhang AJ, Nygaard RM, Endorf FW, Hylwa SA. Stevens-Johnson syndrome and toxic epidermal necrolysis: retrospective review of 10-year experience. Int J Dermatol. 2019; 58 (9): 1069-1077. Available in: https://doi.org/10.1111/ijd.14409

  12. Shi T, Chen H, Huang L, Fan H, Yang D, Zhang D et al. Fatal pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis. Three case reports. Medicine (Baltimore). 2020; 99 (12): e19431. Available in: 10.1097/MD.0000000000019431

  13. Lalosevic J, Nikolic M, Gajic-Veljic M, Skiljevic D, Medenica L. Stevens-Johnson syndrome and toxic epidermal necrolysis: a 20-year single-center experience. Int J Dermatol. 2014; 54 (8): 978-984. Available in: https://doi.org/10.1111/ijd.12702

  14. Lerch M, Mainetti C, Beretta - Piccoli BT, Harr T. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol. 2018; 54 (1): 147-176. Available in: https://doi.org/10.1007/s12016-017-8654-z

  15. McPherson T, Exton L, Biswas S, Creamer D, Dziewulski P, Newell L et al. British Association of Dermatologists' guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in children and young people, 2018. Br J Dermatol. 2019; 181 (1): 37-54. Available in: https://doi.org/10.1111/bjd.17841

  16. Huang Y, Li Y, Chen T. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br J Dermatol. 2012; 167 (2): 424-432. Available in: 10.1111/j.1365-2133.2012.10965.x

  17. Ahmad MS, Frank GS, Hink EM, Palestine AG, Gregory DG, McCourt EA. Amniotic membrane transplants in the pediatric population. J AAPOS. 2017; 21 (3): 215-218. Available in: https://doi.org/10.1016/j.jaapos.2017.04.002




2020     |     www.medigraphic.com